All In MedTech

Device Trial Radar · NCT04279522

The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Aug 31, 2021

Primary completion

Jun 7, 2024

Study completion Jun 7, 2024

Sponsor

Lead sponsor
Neurolief Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Feb 21, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP). This is a prospective, multi-center, 2-arm randomized, double-blind, parallel-group, sham-controlled study. The study will include the following stages: 1. Screening, Eligibility evaluation and Randomization to Relivion®DP vs. Sham control (1:1 randomization) (Baseline - Day 0). 2. Daily treatment period: Active/Sham (Group A/B) treatment protocol (Baseline to end of 8 weeks). 3. Open label phase: Active treatment period of additional 8 weeks. After completion of the open label period the subject's participation in the study will be over.

Conditions

  • MDD

Interventions

  • Relivion®DP- ActiveDevice

    Relivion®DP- Active stimulation device

  • Relivion®DP- ShamDevice

    Relivion®DP- Sham stimulation device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Depressive Symptoms, Measured by HDRS17 Total ScoreTime frame: 8 weeks from treatment initiation

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Kadima Neuropsychiatry Institute

    La Jolla, California

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.